Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Takeda Pharmaceutical Co. Ltd ADR (TAK)

Takeda Pharmaceutical Co. Ltd ADR (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine Business Wire - Mon Jun 27, 5:00AM CDT

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...

TAK : 13.98 (-0.57%)
ARWR : 33.55 (-0.50%)
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine Business Wire - Mon Jun 27, 5:00AM CDT

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...

TAK : 13.98 (-0.57%)
ARWR : 33.55 (-0.50%)
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts Business Wire - Wed Jun 22, 5:55AM CDT

Takeda ( TSE:4502/NYSE:TAK ) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built...

TAK : 13.98 (-0.57%)
As Health Problems Mount Patients Welcome New Treatments FinancialNewsMedia - Tue Jun 14, 10:00AM CDT

Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...

CRDL : 1.5687 (-3.46%)
CRDL.TO : 2.01 (-3.83%)
TAK : 13.98 (-0.57%)
ABT : 108.90 (-0.17%)
BMY : 79.65 (-0.41%)
NVO : 109.65 (-2.87%)
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes Motley Fool - Sat Jun 11, 7:45AM CDT

Improving your investing process tends to have high returns.

TAK : 13.98 (-0.57%)
GSK : 43.61 (-0.21%)
IIPR : 118.19 (+0.74%)
COST : 479.24 (-0.52%)
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial Business Wire - Thu Jun 9, 3:30AM CDT

Takeda ( TSE:4502/NYSE:TAK ) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks...

TAK : 13.98 (-0.57%)
Takeda Canada applauds Quebec's new Rare Disease Policy Newswire.ca - Tue Jun 7, 10:00AM CDT

/CNW/ - Takeda Canada Inc. ("Takeda Canada"), a values-based, R&D-driven biopharmaceutical leader, committed to discovering and delivering life-transforming...

TAK : 13.98 (-0.57%)
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA Business Wire - Tue May 31, 7:00AM CDT

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58 th Annual Meeting of...

TAK : 13.98 (-0.57%)
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna Business Wire - Tue May 31, 2:56AM CDT

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in...

TAK : 13.98 (-0.57%)
MRNA : 146.28 (+0.63%)
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna AccessWire - Tue May 31, 2:40AM CDT

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022...

MRNA : 146.28 (+0.63%)
TAK : 13.98 (-0.57%)

Barchart Exclusives

Warby Parker (WRBY): Demographic Trends Point to a Bullish Case Barchart - Tue Jun 28, 7:30AM CDT
While Warby Parker is one of the most disappointing public market debuts, at its current market value, it might be attractive as eye problems continue to rise. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' : 'America/Chicago' ]] CDT
Reserve Your Spot